Epirubicin/Irinotecan in Advanced Cancers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WASHINGTON, DC-Irinotecan (Camptosar) and epirubicin (Ellence) both have single-agent activity in a number of cancers, and they have different toxicity profiles. John L. Marshall, MD, and colleagues at the Lombardi Cancer Center in Washington, DC, have been working on a phase I trial of epirubicin in combination with irinotecan in patients with various advanced cancers. Dr. Marshall, associate professor and director of Developmental Therapeutics and GI Oncology at the Lombardi Cancer Center reported that doses had to be lowered after the original protocol produced serious myelosuppression in the first four patients treated, but the study has recently reopened.

WASHINGTON, DC—Irinotecan (Camptosar) and epirubicin (Ellence) both have single-agent activity in a number of cancers, and they have different toxicity profiles. John L. Marshall, MD, and colleagues at the Lombardi Cancer Center in Washington, DC, have been working on a phase I trial of epirubicin in combination with irinotecan in patients with various advanced cancers. Dr. Marshall, associate professor and director of Developmental Therapeutics and GI Oncology at the Lombardi Cancer Center reported that doses had to be lowered after the original protocol produced serious myelosuppression in the first four patients treated, but the study has recently reopened.

Irinotecan and epirubicin are given on day 1 and on day 8 every 28 days. Patients are evaluated every 8 weeks for response.

Due to concerns about myelosuppression, the starting irinotecan dose was 100 mg/m², which was about half of the recommended phase II dose. Epirubicin was initially given at 40 mg/m².

"We thought we were in good shape with those starting doses. We were wrong," Dr. Marshall said.

Questioning the Schedule

Two of the first four patients had grade 3/4 febrile neutropenia or thrombocytopenia. One patient had a minor response to treatment. Due to the high level of myelosuppression, the protocol has been altered to begin with irinotecan at 50 mg/m² and epirubicin at 20 mg/m².

"There was evidence of activity in the biliary tree, and we think it would be interesting to study this regimen in gastric gastroesophageal junction cancers, but we need to question the schedule and think about other ways to give this combination," Dr. Marshall said.

His group is also studying irinotecan in combination with exisulind, the sulfone metabolite of sulindac. Dose-finding studies are underway, and two clinical responses have been observed.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content